An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
Por:
Puig, L, Lomaga, M, Hollister, K, Dutronc, Y, Berggren, L, van de Kerkhof, PCM
Publicada:
1 dic 2020
Resumen:
Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806). Patient-reported outcomes investigated included patient global assessment, pruritus, skin pain, health-related quality of life, and work productivity. Ixekizumab-treated patients reported greater improvements in patient-reported outcomes sooner after treatment compared with ustekinumab-treated patients, and maintained greater improvements in patient global assessment scores (ixekizumab 0.72, ustekinumab 1.19; p < 0.001), rates of Dermatology Life Quality Index (0, 1) (ixekizumab 71.3%, ustekinumab 56.6%, p < 0.01), and 36-item Short-form Health survey physical component summary score change from baseline (ixekizumab 5.53, ustekinumab 3.28; p< 0.05) at week 52. While clinically meaningful improvements in patient-reported outcomes resulted with either treatment, ixekizumab provided more rapid improvements in patient-reported outcomes and superior outcomes for some assessments through one year of treatment, while maintaining statistically superior improvements in skin severity, as assessed by either physicians or patients.
Filiaciones:
Puig, L:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Catalonia, Spain
Lomaga, M:
DermEdge Res & Prob Med Res, Mississauga, ON, Canada
Hollister, K:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Dutronc, Y:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Berggren, L:
HaaPACS GmbH, Schriesheim, Germany
van de Kerkhof, PCM:
Radboud Univ Nijmegen, Nijmegen Med Ctr, Nijmegen, Netherlands
Gold, Green Published
|